In vitro interaction of tetrahydrouridine with key human nucleoside transporters.

[1]  R. Liem,et al.  Advances in the diagnosis and treatment of sickle cell disease , 2022, Journal of Hematology & Oncology.

[2]  C. Säll,et al.  In vitro drug-drug interactions of decitabine and tetrahydrouridine involving drug transporters and drug metabolising enzymes , 2021, Xenobiotica; the fate of foreign compounds in biological systems.

[3]  Y. Saunthararajah.  Targeting sickle cell disease root-cause pathophysiology with small molecules , 2019, Haematologica.

[4]  R. Gardner.  Sickle Cell Disease: Advances in Treatment , 2018, Ochsner Journal.

[5]  E. Hazai,et al.  Inhibitor selectivity of CNTs and ENTs , 2018, Xenobiotica; the fate of foreign compounds in biological systems.

[6]  D. Weatherall,et al.  Sickle cell disease , 2018, Nature Reviews Disease Primers.

[7]  J. D. Engel,et al.  Oral tetrahydrouridine and decitabine for non-cytotoxic epigenetic gene regulation in sickle cell disease: A randomized phase 1 study , 2017, PLoS medicine.

[8]  F. Piel,et al.  Sickle Cell Disease. , 2017, The New England journal of medicine.

[9]  F. Hays,et al.  Equilibrative nucleoside transporters—A review , 2017, Nucleosides, nucleotides & nucleic acids.

[10]  S. Iwakawa,et al.  Cellular Uptake of Decitabine by Equilibrative Nucleoside Transporters in HCT116 Cells. , 2015, Biological & pharmaceutical bulletin.

[11]  Huiyu Wang,et al.  Effect of hENT1 polymorphism G-706C on clinical outcomes of gemcitabine-containing chemotherapy for Chinese non-small-cell lung cancer patients. , 2014, Cancer epidemiology.

[12]  J. Martinez-Picado,et al.  Nucleoside transporters and human organic cation transporter 1 determine the cellular handling of DNA‐methyltransferase inhibitors , 2014, British journal of pharmacology.

[13]  Stephen A Baldwin,et al.  The human concentrative and equilibrative nucleoside transporter families, SLC28 and SLC29. , 2013, Molecular aspects of medicine.

[14]  S. Yao,et al.  Role of Human Nucleoside Transporters in the Uptake and Cytotoxicity of Azacitidine and Decitabine , 2012, Nucleosides, nucleotides & nucleic acids.

[15]  Y. Saunthararajah,et al.  Effects of tetrahydrouridine on pharmacokinetics and pharmacodynamics of oral decitabine. , 2012, Blood.

[16]  M. Pastor-Anglada,et al.  SLC28 genes and concentrative nucleoside transporter (CNT) proteins , 2008 .

[17]  James H. Doroshow,et al.  Concentrations of the DNA methyltransferase inhibitor 5-fluoro-2′-deoxycytidine (FdCyd) and its cytotoxic metabolites in plasma of patients treated with FdCyd and tetrahydrouridine (THU) , 2008, Cancer Chemotherapy and Pharmacology.

[18]  Guillermo Garcia-Manero,et al.  Evolution of decitabine development , 2008, Cancer.

[19]  M. Fukushima,et al.  Cellular localization and functional characterization of the equilibrative nucleoside transporters of antitumor nucleosides , 2007, Cancer science.

[20]  Joanne Wang,et al.  Interaction of Organic Cations with a Newly Identified Plasma Membrane Monoamine Transporter , 2005, Molecular Pharmacology.

[21]  S. Yale,et al.  Approach to the vaso-occlusive crisis in adults with sickle cell disease. , 2000, American family physician.

[22]  H. Makita,et al.  Plasma concentration of adenosine during normoxia and moderate hypoxia in humans. , 1999, American journal of respiratory and critical care medicine.

[23]  D. Budman,et al.  Therapy of refractory/relapsed acute leukemia with cytosine arabinoside plus tetrahydrouridine (an inhibitor of cytidine deaminase)--a pilot study. , 1991, Leukemia.

[24]  E. Burchard,et al.  Functional analysis of genetic variants in the human concentrative nucleoside transporter 3 (CNT3; SLC28A3) , 2005, The Pharmacogenomics Journal.

[25]  D. Budman,et al.  Therapy of refractory/relapsed acute myeloid leukemia and blast crisis of chronic myeloid leukemia with the combination of cytosine arabinoside, tetrahydrouridine, and carboplatin , 2004, Cancer Chemotherapy and Pharmacology.